Skip to main
HOWL

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. demonstrates a promising financial outlook supported by its innovative approach to immunotherapy and increased guidance metrics. The company's proprietary PREDATOR platform and INDUKINE molecules position it at the forefront of cancer treatment, potentially increasing its competitive edge in the biopharmaceutical market. Additionally, the reported increase in key financial metrics, alongside improving demand drivers, reflects a robust business model poised for growth amidst the evolving landscape of cancer therapeutics.

Bears say

Werewolf Therapeutics Inc faces a challenging outlook due to a decline in revenues, which have decreased by 30 basis points year-over-year, while expenses increased by 3.8%, leading to a net operating income decrease of 2.6%. Additionally, the average effective rental rate has dropped by 50 basis points year-over-year, impacted by a 4.8% reduction in new lease rates, indicating potential weakness in new business generation. The slowdown in new lease rate growth suggests that demand is not keeping pace with existing supply, which could hinder overall financial stability and recovery for the company.

Werewolf Therapeutics (HOWL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 4 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.